What is Mosaic Immunoengineering Inc's earnings per share (EPS)?

Mosaic Immunoengineering Inc (CPMV) reported diluted earnings per share of $-0.10 for fiscal year 2025. This represents a 23.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Mosaic Immunoengineering Inc Financials

CPMV

Source SEC Filings (10-K/10-Q) Updated May 20, 2026 Currency USD FYE December

This page shows Mosaic Immunoengineering Inc (CPMV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CPMV FY2025 2026-05-20

Shrinking cash reserves and rising obligations show a company conserving spend without rebuilding financial capacity.

From FY2023 to FY2025, R&D spending fell from $435K to $64K and diluted EPS improved from -0.14 to -0.10, yet cash nearly vanished from $156K to $4K while liabilities climbed from $6.1M to $7.5M. The cleaner loss figure therefore reflects a smaller operating footprint more than restored funding capacity.

The balance sheet has become progressively more upside-down: FY2025 assets were only $20K against $7.5M of liabilities, and negative equity widened to -$7.5M. In that state, the reported debt-to-equity ratio near -1.0x is less informative than the basic fact that obligations vastly exceed what the company owns.

Short-term liquidity deteriorated faster than spending: the current ratio fell from 0.04x in FY2023 to 0.003x in FY2025, and cash ended FY2025 at just $4K versus $6.0M of current liabilities. That leaves almost no working-capital cushion, so even a smaller annual burn would not by itself repair near-term financial flexibility.

Financial Health Signals

Financial Profile 17/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Mosaic Immunoengineering Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Mosaic Immunoengineering Inc carries a low D/E ratio of -1.00, meaning only $-1.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Mosaic Immunoengineering Inc's current ratio of 0.00 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-0.10

YoY+23.1%

Mosaic Immunoengineering Inc earned $-0.10 per diluted share (EPS) in fiscal year 2025. This represents an increase of 23.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$4K

YoY-96.9%

5Y CAGR+48.6%

10Y CAGR-48.3%

Mosaic Immunoengineering Inc held $4K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+0.0%

10Y CAGR-33.1%

Mosaic Immunoengineering Inc had 7M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$64K

YoY-65.2%

Mosaic Immunoengineering Inc invested $64K in research and development in fiscal year 2025. This represents a decrease of 65.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

CPMV Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$64K-65.2%	$184K-57.8%	$435K-58.5%	$1.0M	N/A	N/A
SG&A Expenses	N/A	$696K	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$10K+43.8%	$7K	$0	N/A	N/A	N/A
Income Tax	$2K0.0%	$2K0.0%	$2K0.0%	$2K0.0%	$2K+50.0%	$2K
Net Income	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$-0.10+23.1%	$-0.13+7.1%	$-0.14+57.6%	$-0.33+40.0%	$-0.55	$0.00

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$16K	N/A	$16K+0.2%	$16K+1.3%	$16K	N/A	$40K-34.8%	$61K
SG&A Expenses	$139K	N/A	$128K-3.4%	$133K-16.4%	$159K	N/A	$147K	N/A
Operating Income	-$155K	N/A	-$144K+3.0%	-$149K+14.8%	-$175K	N/A	-$186K	N/A
Interest Expense	$2K	N/A	$3K+1.1%	$2K+1.1%	$2K	N/A	$3K	$0
Income Tax	N/A	N/A	$0-100.0%	$2K	$0	N/A	$0	$0
Net Income	-$175K	N/A	-$165K+3.9%	-$172K+5.1%	-$181K	N/A	-$187K	N/A
EPS (Diluted)	$-0.02	N/A	$-0.020.0%	$-0.02+33.3%	$-0.03	N/A	$-0.03+25.0%	$-0.04

CPMV Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$20K-86.0%	$142K-21.1%	$180K-31.3%	$261K-3.0%	$269K+47767.5%	$563
Current Assets	$20K-86.0%	$142K-21.1%	$180K-31.3%	$261K-3.0%	$269K+47767.5%	$563
Cash & Equivalents	$4K-96.9%	$115K-26.4%	$156K-29.2%	$221K-2.4%	$226K+45128.4%	$500
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.5M+8.2%	$6.9M+14.5%	$6.1M+17.6%	$5.1M+67.7%	$3.1M+303411.9%	$1K
Current Liabilities	$6.0M+8.9%	$5.5M+17.0%	$4.7M+20.8%	$3.9M+67.9%	$2.3M+230696.9%	$1K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$7.5M-10.1%	-$6.8M-15.6%	-$5.9M-20.2%	-$4.9M-74.5%	-$2.8M-624679.2%	-$448
Retained Earnings	-$9.5M-7.8%	-$8.8M-11.6%	-$7.9M-14.6%	-$6.9M-52.6%	-$4.5M-885855.4%	-$511

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	N/A	$20K-64.0%	$55K-4.2%	$58K-41.0%	$98K-30.9%	$142K+254.5%	$40K+225.4%	$12K
Current Assets	N/A	$20K-64.0%	$55K-4.2%	$58K-41.0%	$98K-30.9%	$142K+254.5%	$40K+225.4%	$12K
Cash & Equivalents	N/A	$4K-88.6%	$32K-40.7%	$54K-37.6%	$86K-25.3%	$115K+1905.2%	$6K+53.6%	$4K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$7.5M+1.8%	$7.4M+2.3%	$7.2M+1.9%	$7.1M+2.0%	$6.9M+3.8%	$6.7M+3.3%	$6.5M
Current Liabilities	N/A	$6.0M+1.9%	$5.9M+2.5%	$5.8M+2.0%	$5.7M+2.2%	$5.5M+4.5%	$5.3M+3.8%	$5.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	-$7.5M-2.3%	-$7.3M-2.3%	-$7.1M-2.5%	-$7.0M-2.7%	-$6.8M-2.3%	-$6.6M-2.9%	-$6.4M
Retained Earnings	N/A	-$9.5M-1.8%	-$9.4M-1.8%	-$9.2M-1.9%	-$9.0M-2.1%	-$8.8M-1.8%	-$8.7M-2.2%	-$8.5M

CPMV Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	N/A	-$241K+51.5%	-$497K+27.9%	-$690K-1.6%	-$679K	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$0-100.0%	$433K+26.2%	$343K+1141.1%	$28K	N/A
Financing Cash Flow	$0-100.0%	$200K	$0-100.0%	$342K-34.9%	$525K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$4K+87.4%	-$28K-28.9%	-$22K+32.5%	-$32K-11.2%	-$29K-40.4%	-$21K-59.4%	-$13K	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Financing Cash Flow	N/A	$0	$0	N/A	N/A	$130K+766.7%	$15K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CPMV Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	0.00-0.0	0.03-0.0	0.04-0.0	0.07-0.0	0.12-0.4	0.56
Debt-to-Equity	-1.00+0.0	-1.020.0	-1.03+0.0	-1.05+0.0	-1.10+1.2	-2.26
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	-299.0%-0.9pp	-298.1%-112.7pp	-185.4%	N/A	-467.4%	N/A
Current Ratio	N/A	0.000.0	0.010.0	0.010.0	0.020.0	0.03+0.0	0.010.0	0.00
Debt-to-Equity	N/A	-1.000.0	-1.010.0	-1.010.0	-1.010.0	-1.02-0.0	-1.010.0	-1.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$7.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Restart Life NMLSF

$3.9M

Avenue Therapeutics Inc ATXI

$2.8M

Nascent Biotech NBIO

$3.3M

Mynd Life Scienc MYNDF

$895K

GREY MATTERS HEALTH INC, AGNPF

$1.5M

Frequently Asked Questions

What are Mosaic Immunoengineering Inc's total assets?

Mosaic Immunoengineering Inc (CPMV) had $20K in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Mosaic Immunoengineering Inc spend on research and development?

Mosaic Immunoengineering Inc (CPMV) invested $64K in research and development during fiscal year 2025.

How many shares does Mosaic Immunoengineering Inc have outstanding?

Mosaic Immunoengineering Inc (CPMV) had 7M shares outstanding as of fiscal year 2025.

What is Mosaic Immunoengineering Inc's current ratio?

Mosaic Immunoengineering Inc (CPMV) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Mosaic Immunoengineering Inc's debt-to-equity ratio?

Mosaic Immunoengineering Inc (CPMV) had a debt-to-equity ratio of -1.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Mosaic Immunoengineering Inc's debt-to-equity ratio negative or unusual?

Mosaic Immunoengineering Inc (CPMV) has negative shareholder equity of -$7.5M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Mosaic Immunoengineering Inc?

Mosaic Immunoengineering Inc (CPMV) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.